Alpha Layer / Signal Explorer

Signal Explorer

10-K · 10-Q · 8-K · last 6 months · ← back to feed

Clear ×
INSMED Inc INSM

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Oct 20, 2026 8-K 5 signals fired
Other
Rsu Psu Vesting Schedule Disclosed Board Committee Composition Disclosure Classified Board Director Election Executive Transition Gratitude Statement Non Employee Director Compensation Disclosed
Oct 5, 2026 8-K 6 signals fired
Other
Executive Transition Gratitude Statement Patient Retention High
Core
Management Exodus Clinical Trial Result Indication Expansion
SaaS
Efficient Growth
Aug 6, 2026 10-Q 34 signals fired · top 15
Other
Rsu Psu Vesting Schedule Disclosed Financing Activities Cash Flow Disclosure Liquidity Position Snapshot Disclosed Sga Expense Comparison Disclosed Employment Termination Upon Death Operating Lease Rent Expense Disclosed Patient Retention High Cause For Termination Defined New York Jurisdiction Clause Executive Severance Change Of Control Confidential Information Return Obligation Severance Payment Obligation Cash Flow Statement Investing Activities
Core
Clinical Trial Result Secondary Endpoint Mentioned
Aug 6, 2026 8-K 9 signals fired
Other
Transfer And Demand Rights Limitations Ceo Earnings Call Commentary Interim Data Positive Enrollment Ahead Of Schedule Expanded Access Program Active
Core
Indication Expansion Clinical Trial Result
Biotech Risk
Trial Endpoint Missed
Healthcare
Volume Inflecting
Jul 16, 2026 8-K 14 signals fired
Core
Clinical Trial Result Secondary Endpoint Mentioned Indication Expansion Lead Asset Progress Combination Therapy Mentioned Clinical Hold
Other
Patient Retention High Interim Data Positive Expanded Access Program Active Publication Positive Protocol Amended Fda Aligned Kol Endorsement
Biotech Risk
Clinical Hold Active
May 15, 2026 8-K 0 signals fired
No signals above threshold for this filing.
May 7, 2026 10-Q 43 signals fired · top 15
Core
Regulatory Designation Only Clinical Trial Result Indication Expansion
Other
Segment Aggregation Disclosure Liquidity Position Snapshot Disclosed Financing Activities Cash Flow Disclosure Operating Lease Rent Expense Disclosed Rsu Psu Vesting Schedule Disclosed Fast Track Designation Received Capital Raising Uncertainty Disclosed Orphan Status Granted Sga Expense Comparison Disclosed Interim Data Positive Fast Track Granted
Biotech Risk
Trial Endpoint Missed
May 7, 2026 8-K 11 signals fired
Core
Lead Asset Progress Clinical Trial Result Indication Expansion Secondary Endpoint Mentioned Combination Therapy Mentioned
Other
Interim Data Positive Ip Protection Methods Disclosed Kol Endorsement Critical Accounting Policies Disclosure Enrollment Ahead Of Schedule Expanded Access Program Active